![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » MSD INDIA LAUNCHES CANCIDAS IV ANTI-FUNGAL DRUG IN INDIA
MSD INDIA LAUNCHES CANCIDAS IV ANTI-FUNGAL DRUG IN INDIA
September 5, 2006
MSD India, a wholly owned subsidiary of Merck & Co. Inc., launched their latest anti fungal drug, Cancidas IV (caspofugin acetate 50mg/ 70mg), in the Indian pharmaceutical market. The drug is priced at US$ 350 per dose. Pharmabiz (http://pharmabiz.com/article/detnews.asp?articleid=34943§ionid=)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct